This reminds me of GWPH monster move that happened a few years back:
The success of GW in developing pharmaceutical drugs from marijuana sent its shares from less than $9 in 2013 to more than $110 in 2016 and earned it a market value of more than $2.9 billion. And has almost doubled again.
I believe the Zynerba Pharma pipeline is comparable and as deep as GWPH. Exciting times ahead.
Armando the CEO has sold two other biotech companies for north of a billion each.
No Debt
60 Million in cash
The 21 million shares makes ZYNE shares very scarce and the possibility for a blue sky break out in the near future many catalysts.
News 
Market Data 
Discover 
AI
